Kodiak Sciences Inc.

KOD · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
110
SEC Filings

Business Summary

PART I Overview Since its founding in 2009, Kodiak Sciences Inc. (Kodiak, the Company, we or our) has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Our goal is to prevent and treat the major causes of blindness by developing and commercializing next-generation therapeutics to address multiple unmet needs on the spectrum of retinal diseases. Kodiak has developed three late-stage clinical programs based on its internal discovery and d...

Next Earnings

Q2 FY2026 — expected 2026-08-15

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionKODdiscussed_in_filing Cybersecurity
topic_mentionKODdiscussed_in_filing Cybersecurity
topic_mentionKODdiscussed_in_filing Healthcare & Bio
topic_mentionKODdiscussed_in_filing Platform & Ecosystem
topic_mentionKODdiscussed_in_filing Healthcare & Bio
topic_mentionKODdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001193125-26-134887EDGAR81K words
2025-03-272024-12-310000950170-25-046098EDGAR—
2024-03-282023-12-310000950170-24-038025EDGAR—
2023-03-282022-12-310000950170-23-010314EDGAR—
2022-03-012021-12-310000950170-22-002555EDGAR—
2021-03-012020-12-310001564590-21-009946EDGAR—
2020-03-162019-12-310001564590-20-011186EDGAR—
2019-03-272018-12-310001564590-19-009601EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001193125-25-280183EDGAR54K words
2025-08-132025-06-300000950170-25-108033EDGAR—
2025-05-142025-03-310000950170-25-071523EDGAR—
2024-11-142024-09-300000950170-24-127059EDGAR—
2024-08-142024-06-300000950170-24-097010EDGAR—
2024-05-152024-03-310000950170-24-060483EDGAR—
2023-11-142023-09-300000950170-23-063767EDGAR—
2023-08-142023-06-300000950170-23-042479EDGAR—
2023-05-152023-03-310000950170-23-022203EDGAR—
2022-11-092022-09-300000950170-22-023870EDGAR—
2022-08-092022-06-300000950170-22-016151EDGAR—
2022-05-102022-03-310000950170-22-008956EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-310001193125-26-134854EDGAR4K words
2026-03-270001193125-26-127041EDGAR—
2025-12-180001193125-25-324882EDGAR—
2025-11-130001193125-25-280125EDGAR—
2025-08-130000950170-25-107982EDGAR—
2025-06-030001193125-25-134149EDGAR—
2025-05-140000950170-25-071474EDGAR—
2025-03-270000950170-25-046067EDGAR—
2024-11-140000950170-24-127029EDGAR—
2024-08-140000950170-24-096985EDGAR—

110 total filings indexed. 80 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001468748
TickerKOD
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: e93c9ae5a93d3ab281b0ecb33de47848d23ff969b73d6ae106a6e7023d211a75
parent: 148fc28fae3cb1ec615ebfee97d63054c6ae42a62a5db90c9c35b5804aa07503
content hash: 6ee8bc0f26e87d8cc929da0b4689446247b6e675b86ac6fdbc13672221917fc3
signed: 2026-04-13T04:45:54.929Z
sources: 20 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf